Norway Cancer Immunotherapy Market Size & Outlook

The cancer immunotherapy market in Norway is expected to reach a projected revenue of US$ 598.6 million by 2030. A compound annual growth rate of 8.3% is expected of Norway cancer immunotherapy market from 2024 to 2030.

Revenue, 2023 (US$M)
$342.0
Forecast, 2030 (US$M)
$598.6
CAGR, 2024 - 2030
8.3%
Report Coverage
Norway

Norway cancer immunotherapy market highlights

  • The Norway cancer immunotherapy market generated a revenue of USD 342.0 million in 2023 and is expected to reach USD 598.6 million by 2030.
  • The Norway market is expected to grow at a CAGR of 8.3% from 2024 to 2030.
  • In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
  • Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.

Cancer immunotherapy market data book summary

Market revenue in 2023USD 342.0 million
Market revenue in 2030USD 598.6 million
Growth rate8.3% (CAGR from 2023 to 2030)
Largest segmentMonoclonal antibodies
Fastest growing segmentOncolytic Viral Therapies and Cancer Vaccines
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationMonoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines
Key market players worldwidePfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR

Other key industry trends

  • In terms of revenue, Norway accounted for 0.3% of the global cancer immunotherapy market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
  • Spain is the fastest growing regional market in Europe and is projected to reach USD 6,410.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cancer Immunotherapy Market Scope

Cancer immunotherapy market segmentation & scope
Monoclonal Antibodies
Check Point Inhibitors
Oncolytic Viral Therapies and Cancer Vaccines
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and Neck Cancer
Ovarian Cancer
Pancreatic Cancer
Other Applications
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Hospitals and Clinics
Cancer Research Centers
Other End users

Cancer Immunotherapy Market Companies

Name Profile # Employees HQ Website

Norway cancer immunotherapy market size, by product, 2018-2030 (US$M)

Norway Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)

Norway cancer immunotherapy market size, by product, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more